Document:

License Agreement

 Confidential Treatment Requested by Fluidigm Corporation 

Exhibit 10.11A 
  

					
		 		 	8805. LICI.001            
		 		 	UAB Research Foundation

 LICENSE AGREEMENT 
 THIS LICENSE AGREEMENT (this “Agreement”)
dated as of March 7, 2003 (the “Effective Date”), is entered into between The UAB Research Foundation, an Alabama not for profit organization (“UABRF”), having a place of business at 1120G Administration Building, 704 20th
Street, Birmingham, Alabama 35294, and Fluidigm Corporation, a California corporation (“Fluidigm”), having a place of business at 7100 Shoreline Court, South San Francisco, California 94080. 

WHEREAS, UABRF owns or has rights in certain technology regarding nanovolume crystallization arrays. 

WHEREAS, UABRF and Oculus Pharmaceuticals, Inc. (“Oculus”) have entered into that certain License Agreement dated as of
September 21, 2001 (“Oculus Agreement”) pursuant to which UABRF has granted to Oculus an exclusive license to the Oculus Agreement Technology (as defined below), on the terms and conditions of the Oculus Agreement. 

WHEREAS, UABRF and Oculus have terminated the Oculus Agreement effective as of January 30, 2003. 

WHEREAS, UABRF has licensed to Diversified Scientific, Inc. (“DSI”) rights in certain other technology, which certain
technology is identified in the attached Exhibit A (“UABRF/DSI Technology”). 
 WHEREAS, DSI is performing
certain research pursuant to one or more grants, existing as of December 19, 2002, between UAB (as defined below) and DSI under Defense Small Business Innovation Research Program. 

WHEREAS, Fluidigm desires to obtain an exclusive worldwide license under the Licensed IP Rights (as defined below), on the terms and
conditions of this Agreement. 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein
contained, the parties agree as follows: 
 1. DEFINITIONS 

1.1 “Affiliate” shall mean, with respect to any Person, any other Person which directly or indirectly controls, is
controlled by, or is under common control with, such Person. A Person shall be regarded as in control of another Person if it owns, or directly or indirectly controls, at least forty percent (40%) of the voting stock or other ownership interest
of the other Person, or if it directly or indirectly possesses the power to direct or cause the direction of the management and policies of the other Person by any means whatsoever. 

1.2 “Confidential Information” shall mean, with respect to a party, all information of any kind whatsoever, and all
tangible and intangible embodiments thereof of any 

  
  

 
  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
kind whatsoever, which is disclosed by such party to the other party and is marked, identified as or otherwise acknowledged to be confidential at the time of disclosure to the other party.
Notwithstanding the foregoing, Confidential Information of a party shall not include information which the other party can establish by written documentation (a) to have been publicly known prior to disclosure of such information by the
disclosing party to the other party, (b) to have become publicly known, without fault on the part of the other party, subsequent to disclosure of such information by the disclosing party to the other party, (c) to have been received by the
other party at any time from a source, other than the disclosing party, rightfully having possession of and the right to disclose such information, (d) to have been otherwise known by the other party prior to disclosure of such information by
the disclosing party to the other party, or (e) to have been independently developed by employees or agents of the other party without access to or use of such information disclosed by the disclosing party to the other party. 

1.3 “Fluidigm Series C Preferred Stock” shall have the meaning set forth in Section 1.9 of the Master Closing
Agreement. 
 1.4 “Licensed IP Rights” shall mean, collectively, the Licensed Patent Rights and the Licensed
Know-How Rights. 
 1.5 “Licensed Know-How Rights” shall mean all trade secret and other know-how rights in all
information and data disclosed on or before the Effective Date that (i) is not generally known (including, but not limited to, information and data regarding formulae, procedures, protocols, techniques and results of experimentation and
testing), (ii) is developed by Dr. Larry DeLucas in his capacity as a UAB faculty member or by UAB personnel under the scientific direction and scientific supervision of Dr. Larry DeLucas, and (iii) is necessary or useful for
Fluidigm to research, develop, make, use, sell or seek regulatory approval to market a composition, or to practice any method or process, at any time (a) comprising the Oculus Agreement Technology or (b) claimed or covered by in any issued
patent or pending patent application within the Licensed Patent Rights. 
 1.6 “Licensed Patent Rights” shall
mean (a) those certain patent applications and patents listed on Exhibit B hereto; (b) all patent applications heretofore or hereafter filed or having legal force in any country which claim any Oculus Agreement Technology;
(c) all patents that have issued or in the future issue from the patent applications described in clauses (a) and (b) of this Section 1.6, including utility, model and design patents and certificates of invention; and
(d) all divisionals, continuations, continuations-in-part, reissues, renewals, extensions or additions to any such patent applications and patents. 
 1.7 “Master Closing Agreement” shall mean a Master Closing Agreement between Fluidigm, UABRF and Oculus of even date hereof. 

1.8 “NanoScreen Patent Rights” shall mean (a) those certain patent applications and patents listed on
Exhibit B hereto; (b) all patents that have issued or in the future issue from any such patent applications, including utility, model and design patents and certificates of invention; and (c) all divisionals, continuations,
continuations-in-part, reissues, renewals, extensions or additions to any such patent applications and patents. 

  
 - 2 -

  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 1.9 “Oculus Agreement Technology” shall mean collectively, the
technology, processes, inventions, trade secrets, know-how and other proprietary property described in Exhibit C hereto. 
 1.10 “Person” shall mean an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, pool, syndicate, sole
proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein. 

1.11 “Third Party” shall mean any Person other than UABRF, Fluidigm and their respective Affiliates. 

1.12 “UAB” shall mean the University of Alabama at Birmingham. 

1.13 “UABRF/DSI License Agreements” shall mean, collectively, [***]. 

1.14 “UAB Related Entities” shall mean and include UAB, UABRF, University Hospital, The University of Alabama Health
Services Foundation (“UAHSF”), Southern Research Institute and all other entities within the UAB Medical Center, which are under the control of the Board of Trustees of The University of Alabama or are associated with said Board of
Trustees through an affiliation agreement. 
 2. REPRESENTATIONS AND WARRANTIES 

2.1 Mutual Representations and Warranties Each party hereby represents and warrants to the other party as follows: 

2.1.1 Corporate Existence. Such party is a corporation duly organized, validly existing and in good standing under the laws of the
state in which it is incorporated. 
 2.1.2 Authorization and Enforcement of Obligations. Such party (a) has the
corporate power and authority and the legal right to enter into this Agreement and to perform its obligations hereunder, and (b) has taken all necessary corporate action on its part to authorize the execution and delivery of this Agreement and
the performance of its obligations hereunder. This Agreement has been duly executed and delivered on behalf of such party, and constitutes a legal, valid, binding obligation, enforceable against such party in accordance with its terms. 

2.1.3 No Consents. All necessary consents, approvals and authorizations of all governmental authorities and other Persons required
to be obtained by such party in connection with this Agreement have been obtained. 
 2.1.4 No Conflict. The execution
and delivery of this Agreement and the performance of such party’s obligations hereunder (a) do not conflict with or violate any 

  
 - 3 -

  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
requirement of applicable laws or regulations, and (b) do not conflict with, or constitute a default under, any contractual obligation of it. 

2.2 UABRF Representations and Warranties. UABRF represents and warrants to Fluidigm as follows: 

2.2.1 Ownership. UABRF is the sole owner of the Licensed IP Rights (other than those listed under Item No. 3 of
Exhibit B ), and as of the Effective Date has no knowledge of any Third Party having any license or other interest in such Licensed IP Rights. UABRF shall use its commercially reasonable efforts to provide Fluidigm with (a) evidence of
UABRF’s sole ownership of those Licensed IP Rights listed under Item No. 3 of Exhibit B , and (b) a letter from DSI to Fluidigm stating that DSI has no license or other interest in NanoScreen Patent Rights except to
the extent necessary for DSI to perform its research obligations pursuant to the SBIR Grants (as defined below). 
 2.2.2 No
Injunction. No action, suit or proceeding before any court or government body is instituted (or is pending) by any government authority or any other Person to restrain or prohibit this Agreement or the consummation of the transactions
contemplated hereby. No preliminary or permanent injunction or other order issued by any federal or state court of competent jurisdiction preventing this Agreement or the consummation of the transactions contemplated hereby is in effect. 

2.2.3 No Infringement. As of the Effective Date, UABRF and Dr. Larry DeLucas (a) are not aware of any Third Party
patent, patent application or other intellectual property rights that would be infringed by practicing any process or method or by making, using or selling any composition which is claimed or disclosed in the Licensed Patent Rights or which
constitutes Licensed Know-How Rights; (b) are not aware of any infringement or misappropriation by a Third Party of the Licensed IP Rights; and (c) are not aware of any license or other right granted to DSI or any other Third Party under
the NanoScreen Patent Rights. Provided however, UABRF has disclosed to Fluidigm the potential infringement by DSI of the Licensed IP Rights to the extent necessary for DSI to perform its research obligations pursuant to one or more grants (the
“SBIR Grants”), existing as of December 19, 2002, between UAB and DSI under the Defense Small Business Innovation Research (SBIR) Program, with the understanding that neither DSI nor any other third party would have the right to
commercialize any results of such SBIR grants that would infringe the Licensed IP Rights without first obtaining a license from Fluidigm under the Licensed IP Rights. Not later than ten (10) days following the Effective Date, UABRF shall
provide Fluidigm with copies of all documents and instruments relating to such SBIR Grants. 
 3. LICENSE GRANT 

3.1 Licensed IP Rights. UABRF hereby grants to Fluidigm an exclusive, perpetual, irrevocable, royalty-free, worldwide license
(including the right to grant sublicenses) under the Licensed IP Rights. The license grant under the Licensed IP Rights (other than the NanoScreen Patent Rights) is subject to the licenses previously and expressly granted by UABRF to DSI pursuant to
the UABRF/DSI License Agreements regarding the UABRF/DSI Technology only to the extent necessary for DSI to exercise its license rights under the 

  
 - 4 -

  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
UABRF/DSI Technology granted thereunder. The license grant under the NanoScreen Patent Rights is not subject to any previously granted licenses other than those certain rights which may have been
granted to DSI to the extent necessary for DSI to perform its research obligations pursuant to the SBIR Grants. To the extent any of the rights, title and interest in and to the Licensed IP Rights can be neither assigned nor licensed by UABRF to
Fluidigm without (a) the consent of, or (b) breach by UABRF of any agreement with, any Third Party, UABRF hereby irrevocably waives and agrees never to assert such non-assignable and non-licensable rights, title and interest against
Fluidigm or any of Fluidigm’s successors in interest to such non-assignable and non-licensable rights during the term of this Agreement. 
 3.2 Sublicenses. Fluidigm shall not sublicense the Licensed IP Rights prior to the first (1st) anniversary of the Effective Date except in connection with settlement of any action or claim
relating to the technology that is the subject of the Licensed IP Rights. Fluidigm shall give UABRF prompt written notice of each sublicense under this Agreement. Each sublicense shall be subject to the terms and conditions of this Agreement.

 3.3 Availability of the Licensed IP Rights. UABRF shall provide Fluidigm with all information available to UABRF
regarding the Licensed IP Rights. 
 3.4 Reservation of Rights. 

3.4.1 Research Use. UABRF hereby retains the right to, and this Agreement shall not limit UABRF’s ability to, utilize the
Licensed IP Rights for internal research, academic and educational purposes at UAB, UAB Related Entities and academic institution collaborators of UAB, for patient care at UAB and UAB Related Entities, and/or for the performance of services for
for-profit or not-for-profit institutions. 
 3.4.2 Obligations to U.S. Government. UABRF agrees that during the term of
this Agreement UABRF shall not use the Licensed IP Rights in any manner except for internal research, academic and educational purposes at UAB, UAB Related Entities and academic institution collaborators of UAB, for patient care at UAB and UAB
Related Entities, and/or for the performance of services for for-profit or not-for-profit institutions as provided in Section 3.4.1 above and as may be necessary or appropriate to fulfill the obligations of UABRF or UAB under the National
Institutes of Health (“NIH”) grant used to fund the research resulting in the development of certain portion of the Licensed IP Rights. In determining the actions required under such grant, UABRF shall consult with Fluidigm and keep
Fluidigm informed, but UABRF shall have the ultimate right to determine the necessary and appropriate actions relative thereto. UABRF’s rights to the Licensed IP Rights for use in fulfilling UAB’s obligations under the NIH grant shall only
relate to those portions of the Licensed IP Rights funded by such NIH grant. 
 3.5 Non-Assertion Covenant. To the extent
the research activities of DSI conducted in accordance with the SBIR Grants infringe the rights granted to Fluidigm under this Section 3, Fluidigm agrees not to assert such rights against DSI. Fluidigm agrees not to assert against DSI such
rights only to the extent expressly stated herein. No license or other right by Fluidigm in favor of DSI shall be created hereunder by implication, estoppel or otherwise. 

  
 - 5 -

  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 4. LICENSE ISSUE FEE 

Within thirty (30) days after the Effective Date Fluidigm shall (a) pay UABRF the sum in cash of [***] and (b) issue to
UABRF such number of Fluidigm Series C Preferred Stock as provided in Section 2.3 of the Master Closing Agreement. 

5. RESEARCH AND DEVELOPMENT OBLIGATIONS 
 5.1 Research and Development Efforts. Fluidigm shall use commercially reasonable efforts to research, develop and commercialize the Licensed IP Rights as Fluidigm determines commercially feasible.
Appendix 1 of the Sponsored Research Agreement sets forth the components of Fluidigm’s Topaz System which Fluidigm plans to release commercially. 
 5.2 Records. Fluidigm shall maintain records, in sufficient detail and in good scientific manner, which shall reflect all work done and results achieved in the performance of its research and
development regarding the Licensed IP Rights (including all data in the form required under all applicable laws and regulations). 
 5.3 Reports. Within ninety (90) days following the end of each calendar year during the term of this Agreement, Fluidigm shall prepare and deliver to UABRF a written summary report which shall
describe the research and development of the Licensed IP Rights during such year. 
 6. CONFIDENTIALITY 

6.1 Confidential Information. During the term of this Agreement, and for a period of five (5) years following the expiration
or earlier termination hereof, each party shall maintain in confidence all Confidential Information disclosed by the other party, and shall not use, disclose or grant the use of the Confidential Information except on a need-to-know basis to those
directors, officers, employees, consultants, clinical investigators, contractors, (sub)licensees, distributors or permitted assignees, to the extent such disclosure is reasonably necessary in connection with such party’s activities as expressly
authorized by this Agreement. To the extent that disclosure is authorized by this Agreement, prior to disclosure, each party hereto shall obtain agreement of any such person or entity to hold in confidence and not make use of the Confidential
Information for any purpose other than those permitted by this Agreement. Each party shall notify the other promptly upon discovery of any unauthorized use or disclosure of the other party’s Confidential Information. 

6.2 Terms of this Agreement. Except as otherwise provided in Section 6.1 or 6.3, neither party shall disclose any terms or
conditions of this Agreement to any third party without the prior consent of the other party. Notwithstanding the foregoing, prior to execution of this Agreement, the parties have agreed upon the substance of information that can be used to describe
the terms of this transaction, and each party may disclose such information, as modified by mutual agreement from time to time, without the other party’s consent. 
 6.3 Permitted Disclosures. The confidentiality obligations contained in this Section 6 shall not apply to the extent that the receiving party (the “Recipient”) is required
(a) to disclose information by law, order or regulation of a governmental agency or a court of 

  
 - 6 -

  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
competent jurisdiction, or (b) to disclose information to any governmental agency for purposes of obtaining approval to test or market a product, provided in either case that the Recipient
shall provide written notice thereof to the other party and sufficient opportunity to object to any such disclosure or to request confidential treatment thereof. 
 7. PATENTS 
 7.1 Prosecution and Maintenance. Fluidigm shall be
responsible for and shall control, at its sole cost, the preparation, filing, prosecution, defense (including without limitation prosecution, defense and settlement of any interference or opposition) and maintenance of the Licensed Patent Rights.
Fluidigm shall give UABRF an opportunity to review and comment on the text of each patent application within the Licensed Patent Rights before filing, and shall provide UABRF with a copy of such patent application as filed, together with notice of
its filing date and serial number. UABRF shall cooperate with Fluidigm, execute all lawful papers and instruments and make all rightful oaths and declarations as may be necessary in the preparation, prosecution and maintenance of the Licensed Patent
Rights. 
 Enforcement. 
 7.2.1 Each party shall notify the other party of any infringement known to such party of any Licensed Patent Rights and shall provide the other party with the available evidence, if any, of such
infringement. 
 7.2.2 Fluidigm, at its sole expense, shall have the right to determine the appropriate course of action to
enforce the Licensed Patent Rights or otherwise abate the infringement thereof, to take (or refrain from taking) appropriate action to enforce the Licensed Patent Rights, to control any litigation or other enforcement action and to enter into, or
permit, the settlement of any such litigation or other enforcement action with respect to the Licensed Patent Rights, and shall consider, in good faith, the interests of UABRF in so doing. UABRF shall cooperate with Fluidigm in the execution of any
action to enforce the Licensed Patent Rights. Fluidigm shall retain all monies recovered upon the final judgment or settlement of any such suit to enforce the Licensed Patent Rights. 

8. TERMINATION 
 8.1 Expiration. Subject to the provisions of Section 8.2 below, this Agreement shall expire on the expiration of the last to expire of the Licensed Patent Rights. Upon expiration of this
Agreement under this Section 8.1, Fluidigm shall have a paid-up, exclusive, worldwide license under the Licensed Know-How Rights. 
 8.2 Termination by Fluidigm. Fluidigm may terminate this Agreement, in its sole discretion, upon thirty (30) days prior written notice to UABRF. Upon termination of this Agreement by Fluidigm
under this Section 8.2, Fluidigm shall have a paid-up, non-exclusive, worldwide license under the Licensed Know-How Rights. 
 Effect of Expiration or Termination. Expiration or termination of this Agreement shall not relieve the parties of any obligation accruing prior to such expiration or termination, and the provisions
of Sections 6, 7 and 9 shall survive the expiration or termination 

  
 - 7 -

  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
of this Agreement. Except as the parties otherwise agree in writing, termination of this Agreement shall not affect the Master Closing Agreement. 

9. INDEMNIFICATION 
 9.1 Indemnification. Fluidigm shall defend, indemnify and hold the UABRF harmless from all losses, liabilities, damages and expenses (including reasonable attorneys’ fees and costs) resulting
from any claims, demands, actions and other proceedings by any Third Party to the extent resulting from Fluidigm’s use of the Licensed IP Rights under this Agreement. 
 9.2 Procedure. UABRF promptly shall notify Fluidigm of any claim, demand, action or other proceeding for which UABRF intends to claim indemnification. Fluidigm shall have the right to participate
in, and to the extent Fluidigm so desires jointly with any other indemnitor similarly noticed, to assume the defense thereof with counsel selected by Fluidigm; provided, however, that UABRF shall have the right to retain its own counsel, with the
fees and expenses to be paid by UABRF, if representation of UABRF by the counsel retained by Fluidigm would be inappropriate due to actual or potential differing interests between UABRF and any other party represented by such counsel in such
proceedings. The indemnity obligations under this Section 9 shall not apply to amounts paid in settlement of any claim, demand, action or other proceeding if such settlement is effected without the prior express written consent of Fluidigm,
which consent shall not be unreasonably withheld or delayed. The failure to deliver notice to Fluidigm within a reasonable time after notice of any such claim or demand, or the commencement of any such action or other proceeding, if prejudicial to
its ability to defend such claim, demand, action or other proceeding, shall relieve such Indemnitor of any liability to UABRF under this Section 9 with respect thereto, but the omission so to deliver notice to Fluidigm shall not relieve it of
any liability that it may have to UABRF other than under this Section 9. Fluidigm may not settle or otherwise consent to an adverse judgment in any such claim, demand, action or other proceeding, that diminishes the rights or interests of UABRF
without the prior express written consent of UABRF, which consent shall not be unreasonably withheld or delayed. UABRF, its employees and agents, shall reasonably cooperate with Fluidigm and its legal representatives in the investigation of any
claim, demand, action or other proceeding covered by this Section 9. 
 9.3 Insurance. Fluidigm shall maintain
insurance with respect to the research, development and commercialization of products by Fluidigm pursuant to this Agreement in such amount as Fluidigm customarily maintains with respect to the research, development and commercialization of its
similar products. Fluidigm shall maintain such insurance for so long as it continues to research, develop or commercialize any products pursuant to this Agreement, and thereafter for so long as Fluidigm customarily maintains insurance covering the
research, development or commercialization of its similar products. 
 10. MISCELLANEOUS 

10.1 Notices. Any consent, notice or report required or permitted to be given or made under this Agreement by one of the parties to
the other shall be in writing and addressed to such other party at its address indicated below, or to such other address as the addressee shall 

  
 - 8 -

  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
have last furnished in writing to the addressor, and shall be effective upon receipt by the addressee. 
  

			
	If to UABRF:	  	UAB Research Foundation
		  	1120G Administration Building
		  	704 20th Street
		  	Birmingham, Alabama 35294
		  	Attention: Director
		
	If to Fluidigm:	  	Fluidigm Corporation
		  	7100 Shoreline Court
		  	South San Francisco, California 94080
		  	Attention: President
		
	with a copy to:	  	Fluidigm Corporation
		  	7100 Shoreline Court
		  	South San Francisco, California 94080
		  	Attention: General Counsel

 10.2
Assignment. Except as otherwise expressly provided under this Agreement neither this Agreement nor any right or obligation hereunder may be assigned or otherwise transferred (whether voluntarily, by operation of law or otherwise), without the
prior express written consent of the other party; provided, however, that either party may, without such consent, assign this Agreement and its rights and obligations hereunder in connection with the transfer or sale of all or substantially all of
its business, or in the event of its merger, consolidation, change in control or similar transaction. Any permitted assignee shall assume all obligations of its assignor under this Agreement. Any purported assignment or transfer in violation of this
Section 10.2 shall be void. 
 10.3 Applicable Law. This Agreement shall be governed by and construed in accordance
with the laws of the State of Alabama, without regard to the conflicts of law principles thereof. 
 10.4 Entire
Agreement. This Agreement and the Master Closing Agreement (together with the Ancillary Agreements, as defined in the Master Closing Agreement) contain the entire understanding of the parties with respect to the subject matter hereof. All
express or implied representations, agreements and understandings, either oral or written, heretofore made are expressly superseded by this Agreement and the Master Closing Agreement. To the extent that any provision of this Agreement conflicts with
any provision of the Sponsored Research Agreement between the parties of even date hereof (“Sponsored Research Agreement”), the applicable provision of this Agreement shall control and supersede the applicable provision of the Sponsored
Research Agreement. 
 10.5 Independent Contractors. Each party hereby acknowledges that the parties shall be independent
contractors and that the relationship between the parties shall not constitute a partnership, joint venture or agency. Neither party shall have the authority to make any 

  
 - 9 -

  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
statements, representations or commitments of any kind, or to take any action, which shall be binding on the other party, without the prior consent of the other party to do so. 

10.6 Waiver. The waiver by a party of any right hereunder, or of any failure to perform or breach by the other party hereunder,
shall not be deemed a waiver of any other right hereunder or of any other breach or failure by the other party hereunder whether of a similar nature or otherwise. 
 10.7 Force Majeure. Neither party shall be held liable or responsible to the other party nor be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or
performing any term of this Agreement to the extent, and for so long as, such failure or delay is caused by or results from causes beyond the reasonable control of the affected party including but not limited to fire, floods, embargoes, war, acts of
war (whether war be declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, acts of God or acts, omissions or delays in acting by any governmental authority or the other party. 

10.8 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument. 
 IN WITNESS WHEREOF, the parties have executed this Agreement
as of the Effective Date. 
  

			
	UAB RESEARCH FOUNDATION
		
	By	  	/s/ (ILLEGIBLE)
		
	Title	  	Director
	
	FLUIDIGM CORPORATION
		
	By	  	/s/ Gajus Worthington
		
	Title	  	President & CEO

  

	
	Acknowledged and agreed to
	this March 7, 2003.
	
	 /s/ Dr. Larry DeLucas

  Dr. Larry DeLucas

  
 - 10 -

  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 EXHIBIT A 
 UABRF/DSI TECHNOLOGY 
 [***] 

  
 - 11 -

  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 EXHIBIT B 
 PATENT RIGHTS 
  

	1.	[***] 

  

	2.	[***] 

  

	3.	[***] 

  
 - 12 -

  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

  

	4.	[***] 

  

	5.	[***] 

  
 - 13 -

  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 EXHIBIT C 
 OCULUS AGREEMENT TECHNOLOGY 
  

	1.	[***] 

  

	2.	[***] 

  

	3.	Copies of all documentation describing the foregoing, in particular, drawings, operations manuals. 

  
 - 14 -

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.Amended and Restated Letter Agreement

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Exhibit 10.12 
 COY-15-RISC/F269-1 
   S05/1-25730208 

27 March 2008 
 Ms Grace Yow 

  General Manager 

  Fluidigm Singapore Pte Ltd 

  Block 1026, #07-3532 

  Tai Seng Avenue 

  Singapore 534413 
 Dear Ms Grace
Yow, 
 APPLICATION FOR INCENTIVES UNDER THE RESEARCH INCENTIVE SCHEME FOR COMPANIES (RISC) 

  This is with reference to your application of 15 June 2005 and subsequent revisions for incentives under the Research
Incentive Scheme for Companies. This letter amends, restates and replaces our original letter agreement dated 7 October 2005 (the “Prior Letter”), provided that the Supplement to the Prior Letter dated 11 January 2006 (the
“Supplement”) shall remain in full force and effect and all references in the Supplement to the Prior Letter or LOF shall be considered references to this amended and restated letter. 

2 We are pleased to inform you that the Economic Development Board (hereinafter called “EDB”) has agreed to provide a grant not exceeding
S$9,926,000 in total to Fluidigm Singapore Pte Ltd (hereinafter called “the 

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 
Company”) under the RISC for your project on the development of the Fluidigm R&D centre (hereinafter called the “Development Project”), as described in your application. This
grant shall be subject to the following conditions: 
  Project Implementation 

 

	 	(a)	The Company shall implement the Development Project as indicated in the Company’s application dated 15 June 2005 and subsequent revisions.

  

	 	(b)	The Development Project shall meet the project milestones, deliverables and headcount commitment as shown in Annex 1 . 

 

	 	(c)	The Company shall carry out the entire Development Project in Singapore unless otherwise stated. 

 
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

  

	 	(d)	The Company shall employ at least 16 Research Scientists and Engineers in Singapore by 31 December 2007. 

 

	 	(e)	The Company shall employ at least 24 Research Scientists and Engineers in Singapore by 31 December 2009. 

 

	 	(f)	The Company shall incur annual R&D spending of at least S$6.5 million by 31 December 2008 and at least S$8 million by 31 December 2010.

  

	 	(g)	The Company shall be the legal and economic owner of all intellectual property (IP) arising from this project. 

 

	 	(h)	The Company shall engage a Singapore-based IP or legal firm(s) to file, draft and manage all patent applications arising from this project. 

 

	 	(i)	The Company shall manufacture all products developed from this RISC project in Singapore for the lifetime of the products. 

 Supported Period 
  

	 	(j)	Only expenses incurred during the qualifying period, which shall be from 1 August 2005 to 31 July 2010, will be supported. 

 Grant Support 
  

	 	(k)	All manpower, equipment, materials & software, professional services and intellectual property rights supported under this RISC grant shall be used exclusively
for the Development Project and shall follow the administrative guidelines laid out in Annex 2. 

  

	 	(l)	The Company shall not sell, lease, dispose or otherwise transfer the equipment & software supported under this RISC grant to another party during the execution
of the Development Project without first obtaining the written approval of EDB, which if so granted, shall be on such terms as EDB deems fit. The Company shall at all times maintain proper records with respect to the assets acquired through the
grant. 

  

	 	(m)	The Company shall not seek or receive funds from any other incentives offered by other agencies of the Government of Singapore for funding of this Development Project.

  

	 	(n)	All grant monies received shall be used solely for the implementation of this Development project. 

 
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

  Project Management & Co-ordination 

 

	 	(o)	The Company shall appoint a person (hereinafter called the “Principal Investigator”) to lead the Development Project. The Principal Investigator shall be
responsible for the proper management, co-ordination and progress of the Development Project, the management of grants disbursed and all other matters pertaining to the Development Project, including the preparation of claims, submission of audited
statements and progress reports. 

  

	 	(p)	The Principal Investigator shall be deemed as an agent of the Company throughout the Development Project and EDB shall at all times have access to the Principal
Investigator with regards to all matters pertaining to the Development Project. 

  

	 	(q)	The Company shall inform EDB in writing of any change in the Principal Investigator. 

 Other Conditions 
  

	 	(r)	The Company shall permit EDB officers to inspect the premises where the development work is carried out, the Company’s accounts on the development expenditures and
the records on the progress of the Development Project. 

  

	 	(s)	The Company shall be required to provide, through responses to surveys or any other such studies carried out by EDB, relevant information on the Development Project, as
and when requested by EDB. 

  

	 	(t)	If required by EDB, the Company shall submit a report comparing its projections in the application form with the actual realised figures. The template for this report
and the timeline for submission will be provided by EDB. 

 3 In the event the Project is aborted, the Company is to inform EDB in
writing immediately. 
 4 EDB reserves the right to recover from the Company the total amount of grant released to the Company for any breach of
condition under which the RISC grant was approved. 
 5 The Company shall keep the terms and conditions of this RISC grant confidential. Such
information shall not be released to any external party, the public or the press unless prior written consent from EDB is given. 
  

 

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 6 EDB reserves the right to change the terms and conditions of this offer from time to time as may be
specified and deemed necessary by EDB. 
 7 If you are prepared to accept this amended and restated offer of a grant under the conditions
stipulated above, please sign below and return it to EDB within 1 month from the date of this letter, failing which this offer shall be deemed to have lapsed . 
 8 If you have any queries, please contact Ih-Ming CHAN at 6395 7794. For queries on claims, please call the EDAS hotline at 6832 6416. We wish you every success in this project. 

Yours sincerely 
 DR BEH SWAN GIN 

 DIRECTOR 
  BIOMEDICAL SCIENCES
CLUSTER 
 Enclosures: 
 Annex
1     Project Milestones and Deliverables 
 Annex 2     Administrative Guidelines 

Accepted and Agreed 
 FLUIDIGM CORPORATION

                         
                            
  Name: 
  Title: 

 
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Annex 1 
 PROJECT MILESTONES AND DELIVERABLES 
  

	(a)	The Company shall employ at least 16 Research Scientists and Engineers in Singapore by 31 December 2007. 

 

	(b)	The Company shall employ at least 24 Research Scientists and Engineers in Singapore by 31 December 2009. 

 

	(c)	The Company shall incur annual R&D spending of at least S$6.5 million by 31 December 2008 and at least S$8.0 million by 31 December 2010.

  

	(d)	The Company shall be the legal and economic owner of all intellectual property (IP) arising from this project. The economic benefits resulting from the
exploitation of the IP arising from this project shall accrue to the Company. 

  

	(e)	The Company shall engage a Singapore-based IP or legal firm(s) to file, draft and manage all patent applications arising from this project. 

 

	(f)	The Company shall manufacture all products developed from this RISC project in Singapore for the lifetime of the products. 

 

	(g)	The Company shall fulfil the following project milestones as indicated below: 

 

			
	 Milestones
	 	 Date of Completion

		
	TOPAZ Screening Chip	 	
	[***]	 	[***]
	[***]	 	[***]
	TOPAZ Next Generation Screening Chip	 	
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]
	TOPAZ Diffraction Chip	 	
	[***]	 	[***]
	[***]	 	[***]
	[***]	 	[***]

  

 

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

  

			
	 Milestones
	 	 Date of Completion

		
	Dynamic Array IFCs	 	
	     [***]	 	[***]
	     [***]	 	[***]
	     [***]	 	[***]
		
	Next Generation IFCs (Immunoassays, PET Synthesis, DID, Pathogen Detection)	 	
	     [***]	 	[***]

  

 

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

 Annex 2 
 ADMINISTRATIVE GUIDELINES 
  

	1.	The grant shall cover 50% of the actual qualifying manpower costs and 30% of the actual qualifying costs for equipment, materials & software, professional
services and intellectual property rights incurred by the Company on the Development Project during the qualifying period. In the event where qualifying cost items are not used exclusively for the Development Project, the qualifying costs items
shall be suitably pro-rated. The qualifying cost items are listed below, but shall be subject to a total maximum grant of S$9,926,000. Virement from one qualifying cost item to another will not be considered and the grant shall not cover GST
payments. 

  

					
	 Category
	  	    Approved Grant (S$)	 
	 Manpower
	  	 	4,675,380	  
	 Equipment, Materials and Software
	  	 	4,963,380	  
	 Professional services
	  	 	288,000	  
		
	 Total

 
	  	   
	9,926,760  
	    

		  			
	 Total Approved Grant

  (Rounded down to nearest thousand dollars)
	  	 	9,926,000	  

 
  

	2.	The qualifying cost for equipment (less its residual value, if any) is pro-rated based on the number of months the equipment is used for the project (this refers to the
date of delivery to the end of qualifying period) over the approved useful life of equipment. 

 The qualifying
cost of equipment is based on the actual expenses, residual value, number of months that the equipment is used for the project and approved useful life of equipment. 
 The qualifying cost for intellectual property rights (IPR) is pro-rated based on the project duration over the approved useful life of IPR. 

The qualifying cost of IPR is based on the cost of acquiring IPR, project duration and the approved useful life of IPR. 

 

	3.	Disbursements shall be made on a reimbursement basis upon application by the Company at quarterly intervals. Claims must be submitted using the prescribed forms and
shall be certified by the Company’s Chief Financial Officer and the Principal Investigator. The amount disbursed shall be based on the actual qualifying cost item incurred by the Company on the Development Project during the qualifying period.

 The grant will be disbursed as follows: 

 

	 	  (i)	Disbursements of up to a cumulative total 70% of the approved grant amount shall be made upon application by the Company. 

 

	 	  (ii)	The remaining 30% of the grant may be released upon application by the Company on completion of the Development Project. 

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

  
  

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 Confidential Treatment Requested by Fluidigm Corporation 

 

  

	4.	For all claims (except for the final claim), the first 50% of the amount claimed will be disbursed to the Company upon receipt of claim and the remaining 50% will be
disbursed upon the completion of checks. 

  

	5.	The final claim must be submitted within 6 months with complete documentation from the end of the qualifying period (31 July 2010), failing which any claim
will be disqualified. 

  

	6.	For total approved grant exceeding S$100,000, all claims must be externally audited. The audited statement of accounts shall be submitted on an annual basis, as well as
when the Development Project is completed or terminated. The Company shall make available to its auditor this Letter of Offer and its accompanying annexes. The Company shall ensure that the external auditor forwards a copy of the audited accounts
directly to EDB upon completion of the audit. In the event that the external auditor cannot issue an unqualified report, EDB shall have direct access to the external auditor to gather details with regard to the audit findings.

  

	7.	The Company shall submit progress reports to EDB at half-yearly intervals. The disbursement of any grant shall be subject to the Company achieving the project
milestones as stated in the Offer Letter. The final report is to be submitted upon completion of the project. 

  

	[***]	Information has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}]]